{"id":132663,"date":"2026-10-19T17:05:07","date_gmt":"2026-10-19T08:05:07","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/7434-20261019-01_wp_disclosure_update\/"},"modified":"2026-10-19T17:05:07","modified_gmt":"2026-10-19T08:05:07","slug":"7434-20261019-01_wp_disclosure_update","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-7434\/ir\/7434-20261019-01_wp_disclosure_update\/","title":{"rendered":"Notice Regarding Formulation of Recurrence Prevention Measures"},"content":{"rendered":"<p>Following receipt of the Special Investigation Committee&#8217;s report, the company has decided on recurrence prevention measures. Certain business practices were identified as potentially violating the Antimonopoly Act, attributed to excessive competition and corporate culture issues. The company will fundamentally strengthen its compliance framework and enhance internal controls, education, and whistleblower systems. Senior management will issue messages quarterly, and the company will revise internal rules and strengthen the board of directors&#8217; functions.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7434","jir_company_name":"Otake Corporation","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/7434-20261019-01.pdf","jir_short_summary":"Following receipt of the Special Investigation Committee's report, the company has decided on recurrence prevention measures. Certain business practices were identified as potentially violating the Antimonopoly Act, attributed to excessive competition and corporate culture issues. The company will fundamentally strengthen its compliance framework and enhance internal controls, education, and whistleblower systems. Senior management will issue messages quarterly, and the company will revise internal rules and strengthen the board of directors' functions.","jir_summary":"### Overview of Recurrence Prevention Measures\nAfter receiving the Special Investigation Committee's report, the company will pursue a fundamental strengthening of its compliance framework. Senior management will deliver clear messages quarterly, and the company will establish and enforce internal rules that, in principle, prohibit contact with competitors. In addition, the company plans to enhance the board of directors' supervisory function, review internal controls, strengthen compliance training, and improve the effectiveness of the whistleblower system, with the aim of improving organizational culture and the quality of internal audits.\n\n### Impact and Future Initiatives\nThe recurrence prevention measures aim to enforce company-wide codes of conduct and strengthen compliance systems to restore trust with shareholders and investors. Specific initiatives include operating transaction rules that do not presume contact with competitors, considering job rotation, ensuring the effectiveness of supervisory functions, conducting ongoing training, and expanding the internal reporting system.","jir_financial_highlights":"Net Sales: Unknown (Unknown)\nOperating Income: Unknown (Unknown)","jir_category":"","jir_hashtags":"#Otake, #RecurrencePrevention, #StrengtheningInternalControl","jir_key_figures":"Key Figure 1: Unknown (no specific numeric values are provided in the report text)\nKey Figure 2: Unknown\nKey Figure 3: Unknown","jir_meta_title":"Otake Corporation \u2014 Notice Regarding Formulation of Recurrence Prevention Measures | October 2026","jir_meta_description":"Otake Corporation announces recurrence prevention measures following receipt of the Special Investigation Committee report. Planned actions include quarterly messaging from senior management, corporate culture reforms, internal rule revisions, and strengthening of internal controls and training.","jir_og_title":"Otake Corporation \u2014 Notice Regarding Formulation of Recurrence Prevention Measures","jir_og_description":"Announcement regarding receipt of the Special Investigation Committee report and formulation of recurrence prevention measures. The company will fundamentally strengthen its compliance framework, including enhanced messaging from top management and more effective supervisory functions.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59235,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-132663","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notice Regarding Formulation of Recurrence Prevention Measures - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-7434\/ir\/7434-20261019-01_wp_disclosure_update\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-7434\/ir\/7434-20261019-01_wp_disclosure_update\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-7434\/ir\/7434-20261019-01_wp_disclosure_update\/\",\"name\":\"Notice Regarding Formulation of Recurrence Prevention Measures - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-10-19T08:05:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-7434\/ir\/7434-20261019-01_wp_disclosure_update\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-7434\/ir\/7434-20261019-01_wp_disclosure_update\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-7434\/ir\/7434-20261019-01_wp_disclosure_update\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Notice Regarding Formulation of Recurrence Prevention Measures\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Notice Regarding Formulation of Recurrence Prevention Measures - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-7434\/ir\/7434-20261019-01_wp_disclosure_update\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-7434\/ir\/7434-20261019-01_wp_disclosure_update\/","url":"https:\/\/japanir.jp\/en\/company\/company-7434\/ir\/7434-20261019-01_wp_disclosure_update\/","name":"Notice Regarding Formulation of Recurrence Prevention Measures - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-10-19T08:05:07+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-7434\/ir\/7434-20261019-01_wp_disclosure_update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-7434\/ir\/7434-20261019-01_wp_disclosure_update\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-7434\/ir\/7434-20261019-01_wp_disclosure_update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Notice Regarding Formulation of Recurrence Prevention Measures"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"59235","title":"OTAKE CORP","ticker":"7434"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/132663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=132663"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/132663\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=132663"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=132663"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=132663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}